Assertio Therapeutics
Yahoo Finance • 21 days ago
Assertio (ASRT) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool. Date Monday, March 16, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Mark L. ReisenauerChief Financial Officer — Ajay PatelChief Commercial Officer — Paul SchwichtenbergModerator — Dani... Full story
Yahoo Finance • 22 days ago
Earnings week ahead: FDX, BABA, XPEV, MU, GIS, DOCU, OKLO, ACN, and more
[Quarterly Report Financial Analysis and Business Performance Review with Office Tools] Mohamad Faizal Bin Ramli/iStock via Getty Images Wall Street has entered a quieter phase of the earnings calendar, but the macro environment is shouti... Full story
Yahoo Finance • 5 months ago
Assertio narrows 2025 guidance to $110M–$112M as Rolvedon pull-forward shapes cash flow outlook
Earnings Call Insights: Assertio Holdings, Inc. (ASRT) Q3 2025 MANAGEMENT VIEW * Mark L. Reisenauer, CEO, introduced himself in his first earnings call, highlighting his prior experience building and scaling oncology franchises. He sta... Full story
Yahoo Finance • 5 months ago
Assertio Announces Leadership Transition
Appoints Industry Veteran and Current Director Mark L. Reisenauer as CEO, Effective Immediately Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FORE... Full story
Yahoo Finance • 6 months ago
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: FINAL DEADLINE in Securities Lawsuit– Hagens Berman
SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors t... Full story
Yahoo Finance • 6 months ago
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 3-DAY DEADLINE in Securities Lawsuit– Hagens Berman
SAN FRANCISCO, Sept. 21, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors t... Full story
Yahoo Finance • 7 months ago
Spectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit – Hagens Berman
SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors t... Full story
Yahoo Finance • 7 months ago
DEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025
PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of i... Full story
Yahoo Finance • 7 months ago
Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association
Poster presentation will feature new data for SYMPAZAN, the only FDA-approved oral film formulation of clobazam for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age or olderAbstract is n... Full story
Yahoo Finance • 7 months ago
Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025
LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York... Full story
Yahoo Finance • 8 months ago
SHAREHOLDER ALERT: Berger Montague Reminds Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors of Class Action Lawsuit Deadline
PHILADELPHIA, Aug. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of in... Full story
Yahoo Finance • 8 months ago
Assertio narrows 2025 sales guidance to $108M–$118M as transformation accelerates
Earnings Call Insights: Assertio Holdings, Inc. (ASRT) Q2 2025 MANAGEMENT VIEW * CEO Brendan P. O’Grady highlighted that "second quarter net product sales came in on plan at $28.8 million." He emphasized strong provider demand for Rolv... Full story
Yahoo Finance • 8 months ago
ATTENTION NASDAQ: SPPI INVESTORS: Contact Berger Montague About a Spectrum Pharmaceuticals Class Action Lawsuit
PHILADELPHIA, Aug. 07, 2025 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of in... Full story
Yahoo Finance • 11 months ago
Assertio to Participate in the Alliance Global Partners Healthcare Company Showcase on May 21, 2025
LAKE FOREST, Ill., May 19, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O’Grady, Chief Executive Officer, will present at the virtual Alliance Global Partners... Full story
Yahoo Finance • 11 months ago
Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025
LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market... Full story
Yahoo Finance • last year
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O’Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring... Full story
Yahoo Finance • last year
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Inve... Full story
Yahoo Finance • last year
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2... Full story
Yahoo Finance • last year
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NA... Full story
Yahoo Finance • 2 years ago
Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors
LAKE FOREST, Ill., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company that acquires, commercializes and develops safe and effective therapies that ma... Full story
